CA3201273A1 - Intracellular atp enhancer - Google Patents
Intracellular atp enhancerInfo
- Publication number
- CA3201273A1 CA3201273A1 CA3201273A CA3201273A CA3201273A1 CA 3201273 A1 CA3201273 A1 CA 3201273A1 CA 3201273 A CA3201273 A CA 3201273A CA 3201273 A CA3201273 A CA 3201273A CA 3201273 A1 CA3201273 A1 CA 3201273A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- composition according
- atp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020-203725 | 2020-12-08 | ||
| JP2020203725 | 2020-12-08 | ||
| PCT/JP2021/045045 WO2022124325A1 (ja) | 2020-12-08 | 2021-12-08 | 細胞内atp増強剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3201273A1 true CA3201273A1 (en) | 2022-06-16 |
Family
ID=81973288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3201273A Pending CA3201273A1 (en) | 2020-12-08 | 2021-12-08 | Intracellular atp enhancer |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240051971A1 (https=) |
| EP (1) | EP4260860A4 (https=) |
| JP (1) | JPWO2022124325A1 (https=) |
| KR (1) | KR20230118083A (https=) |
| CN (2) | CN121648131A (https=) |
| AU (1) | AU2021398258A1 (https=) |
| CA (1) | CA3201273A1 (https=) |
| WO (1) | WO2022124325A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025258615A1 (ja) * | 2024-06-12 | 2025-12-18 | 学校法人日本医科大学 | 運動機能向上剤、及びそれを含む医薬組成物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0219354Y2 (https=) | 1984-09-13 | 1990-05-29 | ||
| FR2608045B1 (fr) * | 1986-12-12 | 1990-03-02 | Chauvin Laboratoires | Utilisation d'inhibiteurs de xanthine- oxydase, de piegeurs de radicaux libres oxygenes et de chelateurs du fer pour la fabrication d'une composition pharmaceutique destinee au traitement du glaucome et compositions pharmaceutiques destinees au traitement du glaucome |
| DK1757610T3 (da) | 2004-06-14 | 2011-08-01 | Nippon Chemiphar Co | Kondenseret pyrimidinderivat og xanthinoxidaseinhibitor |
| CN101282934A (zh) * | 2005-10-07 | 2008-10-08 | 安斯泰来制药株式会社 | 三芳基羧酸衍生物 |
| ES2884123T3 (es) * | 2013-03-15 | 2021-12-10 | Xortx Therapeutics Inc | Formulaciones de inhibidores de xantina oxidasa |
| US10413546B2 (en) * | 2015-02-24 | 2019-09-17 | National University Corporation Tottori University | Drug for preventing and/or treating dementia |
| KR102600879B1 (ko) | 2015-08-26 | 2023-11-09 | 가부시키가이샤 스타젠 | 세포 내 atp 증강제 |
| JP6867142B2 (ja) | 2016-11-17 | 2021-04-28 | 株式会社スタージェン | パーキンソン症状改善用医薬 |
| WO2018092911A1 (ja) | 2016-11-21 | 2018-05-24 | 株式会社スタージェン | 細胞内atp増強剤 |
| JP6937134B2 (ja) * | 2016-11-21 | 2021-09-22 | 株式会社スタージェン | 細胞内atp増強剤 |
| JP6966840B2 (ja) | 2017-01-24 | 2021-11-17 | 株式会社スタージェン | 神経変性疾患の改善用医薬 |
| JP2018135278A (ja) | 2017-02-20 | 2018-08-30 | 株式会社スタージェン | 循環器疾患及び/又はミトコンドリア病の改善用医薬 |
| TWI780270B (zh) * | 2017-11-28 | 2022-10-11 | 靜岡縣公立大學法人 | 固體分散體 |
| JP2021127289A (ja) | 2018-04-27 | 2021-09-02 | 日本ケミファ株式会社 | 縮合ピリミジン誘導体 |
| WO2020246528A1 (ja) * | 2019-06-04 | 2020-12-10 | 日本ケミファ株式会社 | 痛風又は高尿酸血症の治療薬 |
| CN110156131A (zh) | 2019-06-17 | 2019-08-23 | 厦门翟苑日用品有限公司 | 一种幼儿园健康饮用水集中处理器 |
-
2021
- 2021-12-08 CN CN202511908836.6A patent/CN121648131A/zh active Pending
- 2021-12-08 CA CA3201273A patent/CA3201273A1/en active Pending
- 2021-12-08 CN CN202180082096.9A patent/CN116528840B/zh active Active
- 2021-12-08 WO PCT/JP2021/045045 patent/WO2022124325A1/ja not_active Ceased
- 2021-12-08 EP EP21903424.6A patent/EP4260860A4/en active Pending
- 2021-12-08 KR KR1020237018112A patent/KR20230118083A/ko active Pending
- 2021-12-08 JP JP2022568303A patent/JPWO2022124325A1/ja active Pending
- 2021-12-08 US US18/256,138 patent/US20240051971A1/en active Pending
- 2021-12-08 AU AU2021398258A patent/AU2021398258A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116528840A (zh) | 2023-08-01 |
| AU2021398258A9 (en) | 2024-02-08 |
| US20240051971A1 (en) | 2024-02-15 |
| EP4260860A4 (en) | 2024-11-06 |
| KR20230118083A (ko) | 2023-08-10 |
| CN116528840B (zh) | 2026-01-06 |
| WO2022124325A1 (ja) | 2022-06-16 |
| EP4260860A1 (en) | 2023-10-18 |
| CN121648131A (zh) | 2026-03-13 |
| JPWO2022124325A1 (https=) | 2022-06-16 |
| WO2022124325A8 (ja) | 2023-05-11 |
| AU2021398258A1 (en) | 2023-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9447065B2 (en) | Pharmaceutical composition | |
| JP2021059551A (ja) | フェニルアミノピリミジン誘導体を含む医薬組成物 | |
| EP3718548B1 (en) | Solid dispersion | |
| US20240051971A1 (en) | Intracellular atp enhancer | |
| JP2025061775A (ja) | 痛風又は高尿酸血症の治療薬 | |
| HK40073463A (en) | Therapeutic for gout or hyperuricemia | |
| HK40073463B (en) | Therapeutic for gout or hyperuricemia | |
| EP3981470A1 (en) | Enteric-coated preparation comprising xanthine oxidase inhibitor | |
| CN116687961B (zh) | 一种含有兰索拉唑及碳酸氢钠的干混悬剂及其制备方法 | |
| HK40027115B (zh) | 固体分散体 | |
| AU2006207396A1 (en) | Medicament that is intended for oral administration, comprising a cyclooxygenase-2 inhibitor, and preparation method thereof | |
| HK1195743A (en) | Medicinal composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241125 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241125 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241125 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251024 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251024 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251201 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251201 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251202 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260130 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260217 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260217 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260217 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260217 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260218 |